Exclusive Summary

• Proven Bioequivalence: Robust head-to-head clinical data (Ph1 & Ph3) demonstrating high similarity to the reference product (Remicade®) in pharmacokinetics, efficacy (PASI 75), and immunogenicity.
• Established Commercial Capability: NMPA-approved since Sep 2021 with a stable supply chain backed by a 200 million RMB production line investment.
• Broad Indication Coverage: Covers major autoimmune indications (RA, AS, CD, PsO), serving the high demand for cost-effective biologics in global markets.

Asset Materials

Contact Us for Full Materials